Tomonobu Hasegawa

Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

Mary Lee, Patricia K. Donahoe, Tomonobu Hasegawa et al. · The Journal of Clinical Endocrinology & Metabolism · 1996 · 411 citations · Full text

Medicine, Endocrinology, Oncology +17

SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7

Satoshi Narumi, Naoko Amano, Tomohiro Ishii et al. · Nature Genetics · 2016 · 333 citations

Life Sciences, Genetics, Molecular Genetics +11

Gain-of-Function Mutations in RIT1 Cause Noonan Syndrome, a RAS/MAPK Pathway Syndrome

Yoko Aoki, Tetsuya Niihori, Toshihiro Banjo et al. · The American Journal of Human Genetics · 2013 · 332 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

Developmental Roles of the Steroidogenic Acute Regulatory Protein (StAR) as Revealed by StAR Knockout Mice

Tomonobu Hasegawa, Liping Zhao, Kathleen M. Caron et al. · Molecular Endocrinology · 2000 · 249 citations

Life Sciences, Developmental Biology, Endocrinology +17

Clinical Assessment and Mutation Analysis of Kallmann Syndrome 1 (<i>KAL1</i>) and Fibroblast Growth Factor Receptor 1 (<i>FGFR1</i>, or<i>KAL2</i>) in Five Families and 18 Sporadic Patients

Naoko Sato, Noriyuki Katsumata, Masayo Kagami et al. · The Journal of Clinical Endocrinology & Metabolism · 2004 · 220 citations · Full text

Life Sciences, Genetics, Molecular Genetics +12